Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. More Details
Slightly overvalued with limited growth.
Share Price & News
How has Karyopharm Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: KPTI is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: KPTI's weekly volatility (7%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: KPTI underperformed the US Biotechs industry which returned 23.6% over the past year.
Return vs Market: KPTI underperformed the US Market which returned 39.1% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Karyopharm Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StA Look At Karyopharm Therapeutics' (NASDAQ:KPTI) Share Price Returns
2 months ago | Simply Wall StInsider Buying: Jatin Shah Just Spent US$200k On Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Shares
2 months ago | Simply Wall StThings Look Grim For Karyopharm Therapeutics Inc. (NASDAQ:KPTI) After Today's Downgrade
Is Karyopharm Therapeutics undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: KPTI ($8.84) is trading below our estimate of fair value ($57.62)
Significantly Below Fair Value: KPTI is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: KPTI is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: KPTI is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate KPTI's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: KPTI has negative assets, so we can't compare its PB Ratio to the US Biotechs industry average.
How is Karyopharm Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: KPTI is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: KPTI is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: KPTI is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: KPTI's revenue (33% per year) is forecast to grow faster than the US market (9.3% per year).
High Growth Revenue: KPTI's revenue (33% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if KPTI's Return on Equity is forecast to be high in 3 years time
How has Karyopharm Therapeutics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: KPTI is currently unprofitable.
Growing Profit Margin: KPTI is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: KPTI is unprofitable, and losses have increased over the past 5 years at a rate of 14.6% per year.
Accelerating Growth: Unable to compare KPTI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: KPTI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-7.7%).
Return on Equity
High ROE: KPTI's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
How is Karyopharm Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: KPTI has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: KPTI has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: KPTI has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: KPTI's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: KPTI has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if KPTI has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Karyopharm Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate KPTI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate KPTI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if KPTI's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if KPTI's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of KPTI's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Richard Paulson (54 yo)
Mr. Richard A. Paulson, M.B.A. serves as Director at Karyopharm Therapeutics Inc. since February 26, 2020 and serves as its Chief Executive Officer & President since May 3, 2021. He had been Chief Executiv...
Experienced Management: KPTI's management team is considered experienced (2.4 years average tenure).
Experienced Board: KPTI's board of directors are considered experienced (6.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: KPTI insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.7%.
Karyopharm Therapeutics Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Karyopharm Therapeutics Inc.
- Ticker: KPTI
- Exchange: NasdaqGS
- Founded: 2008
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$663.818m
- Shares outstanding: 75.09m
- Website: https://www.karyopharm.com
Number of Employees
- Karyopharm Therapeutics Inc.
- 85 Wells Avenue
- 2nd Floor
- United States
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/07/25 22:28|
|End of Day Share Price||2021/07/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.